New insider activity at Disc Medicine ( (IRON) ) has taken place on March 27, 2025.
In a recent series of transactions, Director Mona Ashiya and Director Orbimed Advisors LLC each sold 5,738 shares of Disc Medicine stock. Both sales were valued at $310,483, highlighting significant insider activity within the company.
Recent Updates on IRON stock
In recent developments, Disc Medicine has seen positive analyst sentiment and price target increases due to promising advancements in its clinical pipeline. Cantor Fitzgerald raised its price target, citing the potential of bitopertin, an oral GlyT1 inhibitor, in treating rare heme diseases, with expectations of peak sales significantly increasing. Morgan Stanley also assumed coverage with an Overweight rating, highlighting the faster-than-expected market path for bitopertin and the potential of other pipeline assets like DISC-0974 and DISC-3405. Scotiabank raised its price target, emphasizing the de-risked accelerated approval path for bitopertin and the company’s strengthened financial position, which supports operations into 2028. Disc Medicine’s Q4 earnings report underscored its strong financial health and strategic progress, with plans to initiate several Phase 2 trials and prepare for bitopertin’s commercialization.
More about Disc Medicine
YTD Price Performance: -15.47%
Average Trading Volume: 374,032
Technical Sentiment Signal: Hold
Current Market Cap: $1.82B